GlassScriptPhysician profile
Jason A Dundulis
NPI 1548421183
$4,976.13
in general payments reported to CMS, 2019-2025
32 companies · $949 in 2025
The $949 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $204 · 2021: $364 · 2022: $702 · 2023: $860 · 2024: $1,023 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,749.23 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,137.84 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $817.83 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $694.85 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.55 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $346.75 | 2019-2025 | |
| Allergan, INC. | $225.92 | 2019-2020 | |
| Gilead Sciences, INC. | $172.71 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $131.12 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $123.15 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $116.89 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $105.94 | 2019-2024 | |
| Genzyme Corporation | $92.98 | 2022-2025 | |
| Celgene Corporation | $87.57 | 2022-2024 | Zeposia |
| Ucb, INC. | $82.25 | 2019 | |
| Lilly USA, LLC | $53.44 | 2024-2025 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $42.64 | 2023-2025 | Ocaliva |
| Shionogi INC | $36.68 | 2019 | |
| Madrigal Pharmaceuticals | $34.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $26.32 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $21.86 | 2025 | Vowst |
| Ethicon US, LLC | $20.56 | 2023 | Linx Reflux Management System |
| Capsovision, INC. | $19.44 | 2023 | Capsocam Plus |
| Qol Medical, LLC | $18.99 | 2023 | Sucraid |
| Ardelyx, INC. | $17.56 | 2023 | Ibsrela |
| Kci USA, INC. | $16.88 | 2019 | |
| Amgen INC. | $16.68 | 2023 | Avsola, Amjevita |
| Fresenius Kabi USA, LLC | $16.68 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $15.88 | 2022 | |
| Elite Orthopedics, LLC | $14.52 | 2023 | |
| Ironwood Pharmaceuticals, INC | $11.50 | 2020 | |
| Grifols USA, LLC | $10.99 | 2019 | |
| Apollo Endosurgery US INC | $5.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Dundulis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.